Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02260934 · ClinicalTrials.gov registry record · Phase 2
Rituximab and Belimumab for Lupus Nephritis
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT02260934 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 43 participants.
The verdict
NCT02260934, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
In this experimental study, researchers will try to find out if treatment of lupus nephritis with a combination of rituximab and cyclophosphamide (CTX), or a combination of rituximab and CTX followed by treatment with belimumab is safe and if this drug combination can block the immune system attacks.
Interventions
- DRUG Cyclophosphamide
- DRUG Prednisone
- BIOLOGICAL Rituximab
- DRUG Methylprednisolone
- DRUG Diphenhydramine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2015-07-09 |
| Est. Completion | 2019-02-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02260934
The ClinicalTrials.gov registry entry for NCT02260934 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT02260934 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02260934 about?
NCT02260934 is a clinical study titled "Rituximab and Belimumab for Lupus Nephritis". In this experimental study, researchers will try to find out if treatment of lupus nephritis with a combination of rituximab and cyclophosphamide (CTX), or a combination of rituximab and CTX followed by treatment with belimumab is safe and if this drug combination can block the immune system attacks...
What is the current status of trial NCT02260934?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2015-07-09. Estimated completion is 2019-02-08.
What interventions are being tested in trial NCT02260934?
The interventions under investigation include: Cyclophosphamide (DRUG), Prednisone (DRUG), Rituximab (BIOLOGICAL), Methylprednisolone (DRUG), Diphenhydramine (DRUG).
Who is sponsoring clinical trial NCT02260934?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.